DSpace Repository

Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology

Show simple item record

dc.contributor.author Kaplan, Muhammet Ali
dc.contributor.author Isikdogan, Abdurrahman
dc.contributor.author Koca, Dogan
dc.contributor.author Kucukoner, Mehmet
dc.contributor.author Gumusay, Ozge
dc.contributor.author Yildiz, Ramazan
dc.contributor.author Dayan, Adem
dc.contributor.author Demir, Lutfiye
dc.contributor.author Geredeli, Caglayan
dc.contributor.author Kocer, Murat
dc.contributor.author Arslan, Ulku Yalcintas
dc.contributor.author Inal, Ali
dc.contributor.author Akman, Tulay
dc.contributor.author Coskun, Ugur
dc.contributor.author Sener, Nur
dc.contributor.author Inanc, Mevlude
dc.contributor.author Elkiran, Emin Tamer
dc.contributor.author Ozdemir, Nuriye Yildirim
dc.contributor.author Durnali, Ayse Gok
dc.contributor.author Suner, Ali
dc.contributor.author Alici, Suleyman
dc.contributor.author Tarhan, Mustafa Oktay
dc.contributor.author Boruban, Cem
dc.contributor.author Oksuzoglu, Berna
dc.contributor.author Urakci, Zuhat
dc.date.accessioned 2020-07-10T08:34:15Z
dc.date.available 2020-07-10T08:34:15Z
dc.date.issued 2014-11
dc.identifier.citation Kaplan, M.A., Isikdogan, A., Koca, D. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology. (2014) BREAST CANCER. tr_TR
dc.identifier.issn 1340-6868
dc.identifier.issn 1880-4233
dc.identifier.other DOI: 10.1007/s12282-013-0441-y
dc.identifier.uri http://abakus.inonu.edu.tr/xmlui/handle/123456789/16710
dc.description BREAST CANCER Volume: 21 Issue: 6 Pages: 677-683 DOI: 10.1007/s12282-013-0441-y Published: NOV 2014 Document Type:Article tr_TR
dc.description.abstract In this study, we investigated the effect of lapatinib plus capecitabine treatment in HER2-positive breast cancer patients with brain metastasis. Of 405 metastatic breast cancer patients with brain metastases at referral centers in Turkey, 46 were treated with lapatinib plus capecitabine only after the development of brain metastasis. Patients who only received trastuzumab-based therapy after the development of brain metastases were accepted as the historic control group for survival analyses (n = 65). Patients who received both drugs consecutively or sequentially were excluded from the analyses (n = 34). Median age among 46 patients who received lapatinib plus capecitabine therapy was 45 years (27-76), and median time for development of brain metastases was 11.9 months (0-69 months). Twenty-six out of 38 patients who received lapatinib plus capecitabine and had extracranial metastasis showed partial response or stable diseases (68.4 %). Grade 3-4 toxicity was observed in eight patients (17.3 %). Median overall survival (OS) in patients treated with lapatinib plus capecitabine was significantly increased compared to that in patients treated with trastuzumab-based therapy (19.1 vs. 12 months, respectively, p = 0.039). The incidence of cerebral death was slightly decreased in patients who received lapatinib plus capecitabine compared to those who received trastuzumab-based therapy (32 vs. 43.4 %, p = 0.332). In the multivariate analysis, lapatinib plus capecitabine therapy remained an independent positive predictor for survival [odds ratio (OR), 0.57; p = 0.02]. Although this retrospective multicenter study had several limitations, the results suggest that undergoing lapatinib plus capecitabine therapy after the diagnosis of brain metastasis may further improve survival compared to undergoing only trastuzumab-based therapy. tr_TR
dc.language.iso en tr_TR
dc.publisher SPRINGER JAPAN KK, tr_TR
dc.subject Capecitabine tr_TR
dc.subject Breast cancer tr_TR
dc.subject Brain metastases tr_TR
dc.subject Trastuzumab tr_TR
dc.subject Lapatinib tr_TR
dc.subject HER2 tr_TR
dc.title Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology tr_TR
dc.type Article tr_TR


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record